BG108379A - Използване на енантиомерно чист есциталопрам - Google Patents

Използване на енантиомерно чист есциталопрам Download PDF

Info

Publication number: BG108379A
Authority: BG; Bulgaria
Prior art keywords: escitalopram; treatment; pharmaceutical composition; disorder; disorders
Prior art date: 2001-05-01

Application number

BG108379A

Other languages

Bulgarian (bg)

English (en)

Inventor

Connie Sanchez

Jensen Jesper Lyng

Arne Mork

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-01

Filing date

2003-11-24

Publication date

2004-11-30

2003-11-24 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2004-11-30 Publication of BG108379A publication Critical patent/BG108379A/bg

Links

WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title claims abstract description 52
229960004341 escitalopram Drugs 0.000 title claims abstract description 52
238000011282 treatment Methods 0.000 claims abstract description 31
208000020401 Depressive disease Diseases 0.000 claims abstract description 18
239000003814 drug Substances 0.000 claims abstract description 7
208000015238 neurotic disease Diseases 0.000 claims abstract description 7
206010029333 Neurosis Diseases 0.000 claims abstract description 6
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 3
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 3
208000032841 Bulimia Diseases 0.000 claims abstract description 3
206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 3
208000008589 Obesity Diseases 0.000 claims abstract description 3
206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 3
208000031674 Traumatic Acute Stress disease Diseases 0.000 claims abstract description 3
208000022531 anorexia Diseases 0.000 claims abstract description 3
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract description 3
208000010877 cognitive disease Diseases 0.000 claims abstract description 3
206010061428 decreased appetite Diseases 0.000 claims abstract description 3
208000024732 dysthymic disease Diseases 0.000 claims abstract description 3
235000020824 obesity Nutrition 0.000 claims abstract description 3
208000019899 phobic disease Diseases 0.000 claims abstract description 3
208000011117 substance-related disease Diseases 0.000 claims abstract description 3
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims abstract 2
208000030814 Eating disease Diseases 0.000 claims abstract 2
208000019454 Feeding and Eating disease Diseases 0.000 claims abstract 2
208000030990 Impulse-control disease Diseases 0.000 claims abstract 2
208000026345 acute stress disease Diseases 0.000 claims abstract 2
235000014632 disordered eating Nutrition 0.000 claims abstract 2
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 16
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 13
238000011221 initial treatment Methods 0.000 claims description 4
150000003891 oxalate salts Chemical class 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
206010013663 drug dependence Diseases 0.000 claims description 2
208000013403 hyperactivity Diseases 0.000 claims 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
208000035475 disorder Diseases 0.000 abstract description 2
208000024714 major depressive disease Diseases 0.000 abstract 2
206010013654 Drug abuse Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 description 18
229960001653 citalopram Drugs 0.000 description 12
229940068196 placebo Drugs 0.000 description 11
239000000902 placebo Substances 0.000 description 11
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
230000004044 response Effects 0.000 description 7
208000019906 panic disease Diseases 0.000 description 6
208000019901 Anxiety disease Diseases 0.000 description 5
206010041250 Social phobia Diseases 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
230000036506 anxiety Effects 0.000 description 4
208000011688 Generalised anxiety disease Diseases 0.000 description 3
206010033664 Panic attack Diseases 0.000 description 3
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000001430 anti-depressive effect Effects 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
208000029364 generalized anxiety disease Diseases 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
208000028173 post-traumatic stress disease Diseases 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 2
201000001880 Sexual dysfunction Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
231100000872 sexual dysfunction Toxicity 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
208000008811 Agoraphobia Diseases 0.000 description 1
206010034912 Phobia Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940066010 citalopram 40 mg Drugs 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229940041201 escitalopram 10 mg Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
208000030212 nutrition disease Diseases 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
201000001716 specific phobia Diseases 0.000 description 1
230000035882 stress Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)

BG108379A 2001-05-01 2003-11-24 Използване на енантиомерно чист есциталопрам BG108379A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200100684		2001-05-01

Publications (1)

Publication Number	Publication Date
BG108379A true BG108379A (bg)	2004-11-30

Family

ID=8160464

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108379A BG108379A (bg)	2001-05-01	2003-11-24	Използване на енантиомерно чист есциталопрам

Country Status (25)

Country	Link
US (7)	US20040198809A1 (pl)
EP (1)	EP1385503A1 (pl)
JP (1)	JP2004527551A (pl)
KR (2)	KR20040030609A (pl)
CN (1)	CN1509169A (pl)
AR (1)	AR033308A1 (pl)
AT (1)	AT10974U1 (pl)
BG (1)	BG108379A (pl)
BR (1)	BR0208283A (pl)
CA (1)	CA2445843A1 (pl)
CZ (1)	CZ20033267A3 (pl)
EA (1)	EA200301195A1 (pl)
HR (1)	HRP20030744A2 (pl)
HU (1)	HUP0400054A3 (pl)
IL (1)	IL158031A0 (pl)
IS (1)	IS6954A (pl)
ME (1)	MEP5908A (pl)
MX (1)	MXPA03008777A (pl)
NO (1)	NO20034538D0 (pl)
PL (1)	PL367480A1 (pl)
SK (1)	SK14612003A3 (pl)
UA (1)	UA82828C2 (pl)
WO (1)	WO2002087566A1 (pl)
YU (1)	YU85303A (pl)
ZA (1)	ZA200307102B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
EA200301195A1 (ru) *	2001-05-01	2004-04-29	Х. Лундбекк А/С	Применение энантиомерно чистого эсциталопрама
UA80170C2 (en) *	2002-12-23	2007-08-27	Lundbeck & Co As H	Escitalopram hydrobromide
US20050037983A1 (en) *	2003-03-11	2005-02-17	Timothy Dinan	Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) *	2003-07-04	2006-01-25	Lundbeck & Co As H	La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
US20050176680A1 (en) *	2003-12-11	2005-08-11	Sepracor, Inc.	Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
AU2005218713B2 (en) *	2004-03-05	2009-11-19	H. Lundbeck A/S	Crystalline composition containing escitalopram oxalate
US20050196453A1 (en)	2004-03-05	2005-09-08	H. Lundbeck A/S	Crystalline composition containing escitalopram
TWI358407B (en) *	2005-06-22	2012-02-21	Lundbeck & Co As H	Crystalline base of escitalopram and orodispersibl
EP1954257A4 (en) *	2005-10-14	2009-05-20	Lundbeck & Co As H	METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
AU2006304889A1 (en) *	2005-10-14	2007-04-26	H. Lundbeck A/S	Stable pharmaceutical formulations containing escitalopram and bupropion
US20070134322A1 (en) *	2005-12-14	2007-06-14	Forest Laboratories, Inc.	Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) *	2006-01-05	2007-12-12	昆明积大制药有限公司	含西酞普兰和环糊精的抗抑郁口服药用组合物
TW200812993A (en) *	2006-05-02	2008-03-16	Lundbeck & Co As H	New uses of escitalopram
US20070259952A1 (en) *	2006-05-02	2007-11-08	H. Lundbeck A/S	Uses of escitalopram
CA2672925A1 (en) *	2006-10-20	2008-04-24	Ratiopharm Gmbh	Escitalopram and solid pharmaceutical composition comprising the same
JP5404048B2 (ja) *	2006-10-27	2014-01-29	久光製薬株式会社	貼付剤
EP2017271A1 (en)	2007-07-06	2009-01-21	Aurobindo Pharma Limited	Process for the preparation of escitalopram
CN101815519B (zh) *	2007-08-03	2013-08-21	吉瑞工厂	包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法
EP2248808B1 (en) *	2008-01-31	2014-07-16	Takeda Pharmaceutical Company Limited	Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) *	2008-04-24	2009-10-25	Abiogen Pharma Spa	Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
WO2010098230A1 (ja) *	2009-02-27	2010-09-02	久光製薬株式会社	経皮投与製剤
US20180071269A1 (en)	2015-08-12	2018-03-15	Tianxin Wang	Therapeutical methods, formulations and nutraceutical formulations
EP3294337B1 (en) *	2015-05-13	2024-12-18	Arvid Carlsson Research AB	Treatment of debilitating fatigue by combined use of 3(s)-3-[3-(methylsulfonyl)phenyl]-1- propylpiperidine and an anti-depressive agent

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1143702A (pl) *	1965-03-18
US4079135A (en) *	1973-12-13	1978-03-14	Imperial Chemical Industries Limited	Morpholine derivatives as antidepressants
GB1526331A (en) *	1976-01-14	1978-09-27	Kefalas As	Phthalanes
GB8419963D0 (en) *	1984-08-06	1984-09-12	Lundbeck & Co As H	Intermediate compound and method
GB8607313D0 (en) *	1986-03-25	1986-04-30	Ici Plc	Pharmaceutical compositions
GB8814057D0 (en) *	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
US4902710A (en) *	1988-12-14	1990-02-20	Eli Lilly And Company	Serotonin and norepinephrine uptake inhibitors
US5114976A (en) *	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) *	1989-11-02	1990-10-09	Pfizer Inc.	Method of treating anxiety-related disorders using sertraline
US5296507A (en) *	1990-09-06	1994-03-22	H.Lundbeck A/S	Treatment of cerbrovascular disorders
US5708035A (en) *	1991-02-04	1998-01-13	Sepracor Inc.	Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) *	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) *	1995-01-17	1997-05-06	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5554383A (en) *	1995-04-06	1996-09-10	Trustees Of Tufts College	Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) *	1995-04-27	1995-04-27	Astra Ab	A new combination
US5846982A (en) *	1996-06-14	1998-12-08	Eli Lilly And Company	Inhibition of serotonin reuptake
US5747494A (en) *	1996-06-28	1998-05-05	U C B S.A.	Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) *	1996-08-16	1999-09-28	Eli Lilly And Company	Potentiation of serotonin response
ZA977967B (en) *	1996-09-23	1999-03-04	Lilly Co Eli	Combination therapy for treatment of psychoses
US5776969A (en) *	1997-02-27	1998-07-07	Eli Lilly And Company	Treatment of sleep disorders
US6069177A (en) *	1997-07-08	2000-05-30	The Hong Kong University Of Science And Technology	3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) *	1997-09-18	1997-09-18	Astra Ab	A new combination
EP1042310B1 (en) *	1997-11-11	2002-07-31	H. Lundbeck A/S	Method for the preparation of citalopram
EP1100501A4 (en) *	1998-06-30	2002-12-04	Lilly Co Eli	PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6150376A (en) *	1998-08-05	2000-11-21	Georgetown University	Bi- and tri-cyclic aza compounds and their uses
CA2291134C (en) *	1998-10-20	2006-05-23	H. Lundbeck A/S	Method for the preparation of citalopram
AU759716B2 (en) *	1999-04-14	2003-04-17	H. Lundbeck A/S	Method for the preparation of citalopram
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
US6333357B1 (en) *	1999-11-05	2001-12-25	Be Able, Llc	Behavior chemotherapy
UA77650C2 (en) *	1999-12-06	2007-01-15	Lundbeck & Co As H	Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) *	2000-03-13	2002-01-30	Lundbeck & Co As H	Crystalline base of citalopram
WO2001080845A2 (en) *	2000-04-24	2001-11-01	Aryx Therapeutics	(2-aminoethyl) oxime derivatives for the treatment of depression
EA200301195A1 (ru) *	2001-05-01	2004-04-29	Х. Лундбекк А/С	Применение энантиомерно чистого эсциталопрама

2002
- 2002-05-01 EA EA200301195A patent/EA200301195A1/ru unknown
- 2002-05-01 HR HR20030744A patent/HRP20030744A2/xx not_active Application Discontinuation
- 2002-05-01 CZ CZ20033267A patent/CZ20033267A3/cs unknown
- 2002-05-01 CA CA002445843A patent/CA2445843A1/en not_active Abandoned
- 2002-05-01 KR KR10-2003-7014286A patent/KR20040030609A/ko not_active Ceased
- 2002-05-01 HU HU0400054A patent/HUP0400054A3/hu unknown
- 2002-05-01 KR KR1020097027003A patent/KR20100012089A/ko not_active Ceased
- 2002-05-01 MX MXPA03008777A patent/MXPA03008777A/es unknown
- 2002-05-01 YU YU85303A patent/YU85303A/sh unknown
- 2002-05-01 US US10/468,685 patent/US20040198809A1/en not_active Abandoned
- 2002-05-01 CN CNA028092309A patent/CN1509169A/zh active Pending
- 2002-05-01 BR BR0208283-7A patent/BR0208283A/pt not_active IP Right Cessation
- 2002-05-01 ME MEP-59/08A patent/MEP5908A/xx unknown
- 2002-05-01 WO PCT/DK2002/000281 patent/WO2002087566A1/en not_active Ceased
- 2002-05-01 UA UA2003098415A patent/UA82828C2/xx unknown
- 2002-05-01 SK SK1461-2003A patent/SK14612003A3/sk not_active Application Discontinuation
- 2002-05-01 JP JP2002584912A patent/JP2004527551A/ja active Pending
- 2002-05-01 PL PL02367480A patent/PL367480A1/pl not_active Application Discontinuation
- 2002-05-01 EP EP02724141A patent/EP1385503A1/en not_active Withdrawn
- 2002-05-01 IL IL15803102A patent/IL158031A0/xx unknown
- 2002-05-02 AR ARP020101612A patent/AR033308A1/es unknown
2003
- 2003-08-20 US US10/644,587 patent/US20040198811A1/en not_active Abandoned
- 2003-08-20 US US10/644,579 patent/US20040192765A1/en not_active Abandoned
- 2003-08-20 US US10/644,576 patent/US20040192764A1/en not_active Abandoned
- 2003-08-20 US US10/644,577 patent/US20040198810A1/en not_active Abandoned
- 2003-08-20 US US10/644,588 patent/US20040192766A1/en not_active Abandoned
- 2003-09-11 ZA ZA200307102A patent/ZA200307102B/xx unknown
- 2003-09-15 IS IS6954A patent/IS6954A/is unknown
- 2003-10-09 NO NO20034538A patent/NO20034538D0/no not_active Application Discontinuation
- 2003-11-24 BG BG108379A patent/BG108379A/bg unknown
2007
- 2007-09-12 US US11/853,949 patent/US20080004338A1/en not_active Abandoned
2008
- 2008-03-21 AT AT0017508U patent/AT10974U1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2445843A1 (en)	2002-11-07
US20080004338A1 (en)	2008-01-03
ZA200307102B (en)	2004-09-13
YU85303A (sh)	2006-05-25
KR20100012089A (ko)	2010-02-05
US20040198810A1 (en)	2004-10-07
IL158031A0 (en)	2004-03-28
IS6954A (is)	2003-09-15
NO20034538L (no)	2003-10-09
US20040192764A1 (en)	2004-09-30
HRP20030744A2 (en)	2005-06-30
BR0208283A (pt)	2004-03-09
US20040198811A1 (en)	2004-10-07
EP1385503A1 (en)	2004-02-04
US20040192765A1 (en)	2004-09-30
PL367480A1 (pl)	2005-02-21
MEP5908A (xx)	2010-02-10
CN1509169A (zh)	2004-06-30
HUP0400054A2 (hu)	2004-04-28
US20040198809A1 (en)	2004-10-07
WO2002087566A1 (en)	2002-11-07
MXPA03008777A (es)	2004-02-12
NO20034538D0 (no)	2003-10-09
UA82828C2 (en)	2008-05-26
SK14612003A3 (sk)	2004-04-06
CZ20033267A3 (en)	2004-06-16
EA200301195A1 (ru)	2004-04-29
KR20040030609A (ko)	2004-04-09
AT10974U1 (de)	2010-02-15
AR033308A1 (es)	2003-12-10
US20040192766A1 (en)	2004-09-30
JP2004527551A (ja)	2004-09-09
HUP0400054A3 (en)	2007-03-28

Publication	Publication Date	Title
BG108379A (bg)	2004-11-30	Използване на енантиомерно чист есциталопрам
HU208484B (en)	1993-11-29	Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
CN102438603A (zh)	2012-05-02	少肌症的预防和治疗
CN114727989A (zh)	2022-07-08	Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合
JP2007513052A (ja)	2007-05-24	セロトニン再取り込み阻害剤およびアゴメラチンの併用。
US20150335649A1 (en)	2015-11-26	Low dosage combinations of fluoxetine and reboxetine for treating obesity
CN104736151A (zh)	2015-06-24	纤维化的柚皮素和积雪草酸组合治疗
JP2005513105A (ja)	2005-05-12	臨床的うつ病を治療するためのデオキシペガニンの使用
Simon et al.	2001	Citalopram for social phobia: a clinical case series
AU2002254870A1 (en)	2002-11-11	The use of enantiomeric pure escitalopram
AU2008201217A1 (en)	2008-04-03	The use of enantiomeric pure escitalopram
US20070123584A1 (en)	2007-05-31	Method of treating premenstrual dysphoric disorder with escitalopram
HK1067047A (en)	2005-04-01	The use of enantiomeric pure escitalopram
WO2002076461A1 (en)	2002-10-03	Combination of reboxetine and citalopram
WO2025219389A1 (fr)	2025-10-23	Compositions contenant une combinaison synergique de mémantine et de vitamine d
JP2009545573A (ja)	2009-12-24	サレデュタントとおよびセロトニン再取込みの選択的阻害剤またはセロトニン／ノルエピネフリン再取込みの阻害剤とを組み合わせて含有する医薬組成物
Srinivasan et al.	2013	Melatonin in mood disorders and agomelatine’s antidepressant efficacy
RU2024122065A (ru)	2024-09-06	Композиции и способы лечения депрессии
WO2003072093A1 (en)	2003-09-04	METHOD OF TREATMENT OF HYPERTENSION USING SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs)
HRP20100463A2 (hr)	2012-02-29	Upotreba čistog enantiomernog citaloprama
WO2023236781A1 (zh)	2023-12-14	治疗精神类疾病的方法
JPWO2023131920A5 (pl)	2026-01-16
Iancu et al.	0	THE ROLE OF SEROTONIN IN DEPRESSION AND ANXIETY DISORDERS
De Nayer et al.	2000	P01. 42 Symptom relief obtained with venlafaxine versus fluoxetine in depressed patients with concomitant anxiety
De Clercq et al.	2000	P01. 41 Efficacy of venlafaxine in depressed patients after failure with prior antidepressant treatment